Infarama SRL
15.3 FTEThe score of Infarama shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity 0 % Total assets +33 % Headcount (avg FTE) +63 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Infarama's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 07 Jul 2026
- Year ended 31 Dec 2024filed on 09 May 2025
- Year ended 31 Dec 2023filed on 05 Jul 2024
- Year ended 31 Dec 2022filed on 25 Jul 2023
- Year ended 31 Dec 2021filed on 20 Jun 2022
Infarama's financial analysis
- Solvency27.6%sector median: 60.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Infarama
Infarama's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0806.647.149
- VAT number
- BE0806647149
- Peppol
- Registered · 0208:0806647149 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 26 Sep 2008
- Registered office
- 1853 Grimbergen
- Size
- Small · 15.3 FTE
- Latest accounts
- 2025 · filed on 07 Jul 2026
- Activity
- Research and experimental development on other natural sciences and engineering (NACE 72109)
Infarama (SRL) has been based in Grimbergen since 2008, active in: research and experimental development on other natural sciences and engineering. For 2025, it reports a net profit of 704,227 € and equity of 450,269 €; its revenue is not published. With 15.3 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 27.6%, below the median of its sector (60.4%).
Companies similar to Infarama
Companies in the same business, of comparable size and area, outside its group.
- BWAT All other professional, scientific and technical activities n.e.c. Jodoigne · balance sheet €1.21m
- FADI Research and experimental development on natural sciences and engineering Ghent · balance sheet €1.42m
- Coherence All other professional, scientific and technical activities n.e.c. Ixelles · balance sheet 80,498 €
- DECOCK & Co Research and experimental development on natural sciences and engineering Langemark-Poelkapelle · balance sheet €1.31m
- Bef4U All other professional, scientific and technical activities n.e.c. Sombreffe · balance sheet €1.44m
- Xedev Other information service activities Zele · balance sheet €2.72m
- NineSigma Europe Business and other management consultancy activities Leuven · balance sheet €1.10m
- Climate LAB Business and other management consultancy activities Ghent · balance sheet €2.44m
Frequently asked questions about Infarama
What is the revenue of Infarama?
Infarama files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Infarama?
In Belgium, the VAT number is the company number prefixed with BE: BE0806647149 for Infarama, if the company is VAT-registered. Its company number (CBE) is 0806.647.149.
Where is the registered office of Infarama?
According to the CBE register, the registered office of Infarama is in 1853 Grimbergen.
What is the equity of Infarama?
At the close of the 2025 financial year, the equity of Infarama amounts to 450,269 €, a solvency of 27.6% of total assets.
How many people work at Infarama?
15.3 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Infarama?
The register lists 4 active mandates at Infarama. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Infarama
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →